Answers are grounded in this paper and cite their sources.
EDITOR—We should like to raise some concerns about the ATAC (arimidex, tamoxifen alone or in combination) trial, which was reported on in the Lancet after only half the time stipulated in the protocol (2.5 years instead of 5).1 Ravdin has raised important points: “Early reporting rules can powerfully …
No takes yet. Share an insight, caveat, or question.
Heather Goodare (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: